Abstract: Epithelial to mesenchymal transition (EMT) is associated with resistance during EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. Here, we investigated whether EMT is associated with acquired resistance to 3rd generation EGFR-TKIs, and we explored the effects of cyclin-dependent kinase 7 (CDK7) inhibitors on EMT-mediated EGFR-TKIs resistance in non-small cell lung cancer (NSCLC). We established 3rd generation EGFR-TKI resistant cell lines (H1975/WR and H1975/OR) via repeated exposure to WZ4002 and osimertinib. The two resistant cell lines showed phenotypic changes to a spindle-cell shape, had a reduction of epithelial marker proteins, an induction of vimentin expression, and enhanced cellular mobility. The EMT-related resistant cells had higher sensitivity to THZ1 than the parental cells, although THZ1 treatment did not inhibit EGFR activity. This phenomenon was also observed in TGF-β1 induced EMT cell lines. THZ1 treatment induced G2/M cell cycle arrest and apoptosis in all of the cell lines. In addition, THZ1 treatment led to drug-tolerant, EMT-related resistant cells, and these THZ1-tolerant cells partially recovered their sensitivity to 3rd generation EGFR-TKIs. Taken together, EMT was associated with acquired resistance to 3rd generation EGFR-TKIs, and CDK7 inhibitors could potentially be used as a therapeutic strategy to overcome EMT associated EGFR-TKI resistance in NSCLC.

Keywords: lung cancer; CDK7; EGFR-TKIs; EMT; THZ1; resistance

1. Introduction

Lung cancer is the leading cause of cancer mortality globally [1]. Resistance to lung cancer therapies contributes to the higher death rates of these patients. A targeted therapy utilizing an epidermal growth factor receptor (EGFR) mutation improves the survival rate of patients until resistance begins to develop [2]. First-generation EGFR-tyrosine kinases (TKIs) therapy exhibits efficacy for a short time (<2 years). However, inevitably, resistance gradually develops, leading to disease progression [3]. Various resistance mechanisms for EGFR-TKIs have been reported in previous
research, including T790M point mutations, EGFR amplification, ERBB2 amplification, small cell lung cancer transformation, MET amplification, PI3K mutations, epithelial-mesenchymal transition (EMT), BRAF mutations, and KRAS mutations [3–6]. The T790 mutation is considered the most prevalent type (40–50% of cases) of resistance to the first-generation EGFR-TKIs. Recently, a third-generation drug, osimertinib and WZ4002, has been developed to overcome T790M-associated resistance [7,8]. However, most of the mechanisms involved in third-generation EGFR-TKI resistance have not yet been elucidated. As such, the development of methods to overcome acquired resistance to 3rd generation EGFR inhibitors is critical for improving the prognosis of patients.

EMT is a biological process via which cells undergo a switch from the polarized epithelial phenotype to the mesenchymal fibroblastoid phenotype, and it is considered to be one of the resistance mechanisms. EMT is involved in several diverse processes, including embryonic development, chronic inflammation, fibrosis, tumorigenesis, invasion, metastasis, and drug resistance [9–13]. As a result of EMT, cells downregulate the expression of epithelial proteins such as E-cadherin and upregulate the expression of mesenchymal proteins, including vimentin. In addition, cells undergoing EMT are characterized by the loss of apico-basal polarity and intact cell-cell junctions followed by the acquisition of front-rear polarity and morphologic changes to a spindle shape with remodeling of the cytoskeleton [14]. This EMT program enhances their invasive capacity, therapeutic resistance, and the cancer stem-cell-like properties of the cells [13]. EMT has also been reported to be one of the mechanisms of EGFR-TKI resistance [6]. However, how to overcome EMT related EGFR-TKI resistance is unclear at this time.

Cyclin-dependent kinases (CDKs) are a family of serine-threonine kinases that play an important role in cell cycle progression. Over 90% of tumors have upregulated CDKs due to changes in the expression and genetic variation of CDKIs. Based on this, CDKs inhibitors have potential as anticancer agents that could inhibit the growth of various cancers. In particular, CDK7 acts as a master regulator of transcription and is known to modulate RNA polymerase II activity [15]. Recently, CDK7 inhibitors have been reported to inhibit abnormal cell growth associated with hematologic malignancies and breast, esophageal, and small cell lung cancer [16–19]. Specifically, small cell lung cancer studies have shown that the action of THZ1 significantly reduces the activity of super-enhancers and their associated oncogene transcription factors [17], which suggests that CDK inhibitors have potential as anticancer agents.

This study evaluated whether EMT was expressed in resistant cell lines generated by treatment with 3rd generation EGFR-TKIs, and we also analyzed the effect of CDK7 inhibitors on the EMT-associated resistant cells to evaluate a potential therapeutic strategy to overcome EMT related EGFR-TKI resistance.

2. Materials and Methods

2.1. Cell Culture and Reagents

The H1975 and HCC827 cell lines were obtained from the American Type Culture Collection (Rockville, MD, USA), and the PC-9 cell line was a kind gift from Dr. Kazuto Nishio (National Cancer Center Hospital, Tokyo, Japan). The cells were cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) that contained 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin (Invitrogen) at 37 °C in an atmosphere with 5% CO₂. Osimertinib, WZ4002, and THZ1 were purchased from Selleck Chemicals (Houston, TX). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution and TGF-β1 were purchased from Sigma (St. Louis, MO, USA) and R&D Systems (Minneapolis, MN, USA), respectively. QS1189 was kindly provided by Qrient Co., Ltd. (Seongnam, Korea).

2.2. Establishment of the 3rd Generation EGFR-TKIs-Resistant Cells

The H1975 harbors the EGFR L858R/T790M double mutation. To establish a cell with acquired resistance to 3rd generation EGFR-TKIs including osimertinib and WZ4002, H1975 cells were initially
Cells were treated to 10 nM osimertinib or WZ4002 for 48 h. The surviving cells were continuously exposed to increasing concentrations for 3 months, as reported in previous studies [20–24]. The resistant cells (H1975/OR and H1975/WR) were cultured in a drug-free medium for >1 week before the experiment to eliminate the effects of each drug. The resistant cell lines were authenticated using STR analysis and confirmed to be mycoplasma free using standard methods.

2.3. Cellular Viability Assays

Cells (1×10⁴) were seeded in 96-well sterile plastic plates overnight and then treated with the relevant drugs. After 72 h, 15 µL of MTT solution (5 mg/mL) was added to each well, and the plates were incubated for 4 h. Crystalline formazan was solubilized with 100 µL of 10% (w/v) SDS solution for 24 h. The absorbance at 595 nm was read spectrophotometrically using a microplate reader. Cell counting was determined using an ADAM-MC automatic cell counter (NanoEnTek, Seoul, Korea) according to the manufacturer’s instructions. The results represent at least three independent experiments, and the error bars signify the standard deviation from the mean. The IC₅₀ values were determined using GraphPad Prism software (GraphPad, Inc., La Jolla, CA, USA).

2.4. Immunoblotting

Whole cell lysates were prepared using EBC lysis buffer (50 mM Tris-HCl [pH, 8.0], 120 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 0.3 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium orthovanadate, 0.5% NP-40, and 5 U/mL aprotinin) and then centrifuged. The resulting supernatants (20 µg) were separated on 8% to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and then transferred onto polyvinylidene difluoride membranes (Invitrogen). The membranes were probed with antibodies against p-EGFR (1:1000, Tyr1173, sc-101668), EGFR (1:2000, sc-373749), p-Erk (1:1000, Thr202/Tyr204, sc-16982), Erk (1:3000, sc-94), Akt (1:3000, sc-5298), E-cadherin (1:1000, sc-71008), CDK7 (1:2000, sc-7344), ß-catenin (1:1000, sc-71059), desmoplakin (1:1000, sc-390975), cytokeratin-8/18 (1:1000, sc-70939) and ß-actin (1:5000, sc-47778; all from Santa Cruz Biotechnology, Santa Cruz, CA, USA), p-Akt (1:1000, Ser473, #4060), vimentin (1:1000, #5741), RNAPII CTD p-Ser2 (1:1000, #13499), RNAPII CTD p-Ser5 (1:1000, #13523), RNAPII CTD p-Ser7 (1:1000, #13780), RNAPII CTD (1:2000, #2629), PARP (1:1000, #9541) and caspase 3 (1:1000, #9661; all from Cell Signaling Technology, Beverly, MA, USA) and then the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody. All membranes were developed using ECL kits (Perkin Elmer, Waltham, MA, USA). The immunoblotting is representative of three independent experiments.

2.5. Invasion and Migration Assays

The cell migration and invasion assays were conducted using Transwells (6.5 mm diameter, 8 mm pore size polycarbonate membrane), which were obtained from Corning (Cambridge, MA, USA). The cells (1×10⁵) in 200 µL medium were placed in the upper chamber, and the lower chamber was filled with 1 mL of serum-free media supplemented with 0.1% bovine serum albumin. After incubation for 24 h, the cells that migrated to the lower surface of the filters were stained with a Diff-Quick kit (Fisher Scientific, Pittsburgh, PA, USA), and then they were counted under a microscope. The invasion assays used the same procedure with filters that were pre-coated with Matrigel (BD Biosciences, Bedford, MA, USA) and then the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody. All membranes were developed using ECL kits (Perkin Elmer, Waltham, MA, USA). The immunoblotting is representative of three independent experiments.

2.6. Flow Cytometry Analysis

The cells were treated with 0.1 µM THZ1 for the indicated time. To determine their cell cycle process, the cells were fixed in 70% ethanol at −20 °C for 1 h to a few days, incubated with 5 µL RNase (10 mg/mL), and finally stained with 10 µL propidium iodide (1 mg/mL). The cellular DNA content in the treated cells was analyzed with a FACScan flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Apoptosis was quantified using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide apoptosis kit (BD Biosciences) in accordance with the manufacturer’s protocol. The cells were
Cells 2020, 9, 2596 4 of 14

resuspended in Annexin V-binding buffer (150 mM NaCl, 18 mM CaCl₂, 10 nM HEPES, 5 mM KCl, and 1 mM MgCl₂). FITC-conjugated Annexin V (1 µg/mL) and propidium iodide (50 µg/mL) were then added to the cells and incubated for 30 min at room temperature in the dark. Analyses were performed using a FACScan flow cytometer. Data were analyzed with CellQuest software (BD Biosciences).

2.7. Statistics

Data are presented as the mean ± standard deviation. P values were determined using unpaired or paired t-tests between groups using GraphPad Prism software.

3. Results

3.1. The Induction of EMT in Acquired Resistance to 3rd Generation EGFR-TKIs

To investigate the mechanisms of acquired resistance to 3rd generation EGFR-TKIs, we established H1975/WR and H1975/OR through stepwise selection in WZ4002 or osimertinib, respectively, as described in previous studies [20–24]. Both resistant cell lines exhibited 10-fold or greater resistance against each drug compared with the parent cells (WZ4002 IC₅₀ = 106.9 nM in H1975 and 1494 nM in H1975/WR, osimertinib IC₅₀ = 39.9 nM in H1975 and 1352 in H1975/OR; Figure 1A). In addition, C797S mutation that can confer resistance to osimertinib was not observed in both resistant cells (data not shown).

These resistant cells showed an increased number of spindle-shaped cells that resembled EMT changes (Figure 1B). To determine the induction of EMT in the resistant cells, we analyzed the expression of marker proteins of the epithelial and mesenchymal phenotypes by using western blots (Figure 1C). Compared with the H1975 cells, the epithelial marker proteins E-cadherin, β-catenin, EpCAM, desmoplakin, and cytokeratin-8/18 were significantly reduced in both resistant cell lines, whereas vimentin expression was increased. In addition, the expression and activity of EGFR were both reduced in the resistant cells, but the activity of Akt was significantly upregulated.

Next, we investigated their migratory and invasive abilities, which are considered functional hallmarks of EMT. We found that the migratory and invasive abilities of the resistant cells were significantly enhanced relative to the parental cells (Figure 1D,E). Taken together, these data suggested that the acquisition of resistance to 3rd generation EGFR-TKIs induced molecular changes that were consistent with EMT.
Figure 1. Induction of EMT in cells with acquired resistance to WZ4002 or osimertinib. (A) Cells were treated with the indicated doses of WZ4002 or osimertinib for 72 h, and cell viability was determined by an MTT assay. IC$_{50}$ values were calculated with GraphPad software through three independent experiments. (B) H1975 parental cells and the resistant cell lines (H1975/WR and H1975/OR) were evaluated for morphologic changes that were consistent with EMT using a light microscope. (C) EGFR signaling and EMT-related molecules were analyzed by western blotting. (D,E) Cells were seeded onto either collagen or Matrigel-coated polycarbonate filters to determine their migratory and invasive potentials, respectively. Cells were incubated in modified Boyden chambers for 24 h, and the cells that penetrated the filter were stained and counted using a light microscope. Experiments were conducted in triplicate. The bars represent the standard deviations. *** $P < 0.0005$ compared with H1975 cells.

3.2. Efficacy of the CDK7 Inhibitor on EMT-Induced Cells

Previous studies showed that CDK7 was associated with EMT, but it is controversial whether targeting CDK7 can overcome EMT [25–28]. To determine the effect of CDK7 inhibition on the resistant
cells, we used THZ1 and QS1189 as CDK7 inhibitors. QS1189 was developed as a novel CDK7 inhibitor in a previous study [16]. As shown in Figure 2A, both resistant cell lines were more sensitive to CDK7 inhibitors than the parental cells (THZ1 IC\textsubscript{50} = 379 nM in H1975, 83.4 nM in H1975/WR, 125.9 nM in H1975/OR; QS1189 IC\textsubscript{50} = 755.3 nM in H1975, 232.8 nM in H1975/WR, 275.3 nM in H1975/OR). CDK7 kinase activity is involved in phosphorylation of the CTD of RNAPII, which plays a role in transcription initiation and RNAPII procession [15,29,30]. To evaluate the inhibitory efficacy of CDK7 substrates on the parental and resistant cells, we performed Western blotting following treatment with THZ1 (Figure 2B). The inhibitory effect of THZ1 on the activity of RNAPII-CTD was similar in the H1975 and H1975/OR cells. However, the H1975/WR cells had inhibition of RNAPII-CTD phosphorylation at Ser2, Ser5, and Ser7 at the lowest concentration of THZ1. In addition, THZ1 treatment did not inhibit the activity of EGFR or Akt, but the activity of Erk showed a dose-dependent induction.

Figure 2. Effects of CDK7 inhibitors on cells with acquired resistance to WZ4002 or osimertinib. (A) Cells were treated with the indicated doses of THZ1 or QS1189 for 72 h, and cell viability was determined using MTT assays. The IC\textsubscript{50} values of the CDK7 inhibitors were calculated. (B) Cells were treated with the indicated doses of THZ1 for 6 h. The indicated protein levels were analyzed by western blotting.
To assess whether the induction of EMT can affect the sensitivity to CDK7 inhibitors, we examined the response to THZ1 under conditions of TGF-β1-induced EMT. In similar to our previous studies [22,31], TGF-β1 treatment led to the induction of EMT through the reduction of E-cadherin and an increase of vimentin (Figure 3A). When the cells were pretreated with TGF-β1 to induce EMT, their sensitivity to THZ1 was increased (Figure 3B,C). Consistent with previous studies, the induction of EMT reduced their sensitivity to osimertinib. In addition, TGF-β1 treatment did not affect the inhibition of RNAPII-CTD phosphorylation by THZ1 (Figure 3D). Taken together, the induction of EMT could affect the sensitivity of cells to CDK7 inhibitors.

3.3. Induction of Cell Cycle Arrest and Apoptosis by CDK7 Inhibitors

We have previously observed that the mechanisms of the anticancer activity of CDK7 inhibitors were associated with cell cycle arrest and the apoptosis of various cancer cells [16,32–34]. Thus, we analyzed the cell cycle and apoptosis. As shown in Figure 4, THZ1 treatment induced G2/M arrest and apoptosis in all cells (Figure 4A,B). Interestingly, the rates of G2/M arrest and apoptosis were higher in both resistant cell lines than in the parental cells (G2/M arrest = 31.6% in H1975, 50.9% in HCC827).

**Figure 3.** Effects of the CDK7 inhibitors on TGF-β1 stimulated EMT. (A) Cells were treated with TGF-β1 (10 ng/mL) for 24 h, and the levels of EMT-related proteins were analyzed by western blotting. (B) Cells were pretreated with TGF-β1 (10 ng/mL) for 24 h and then incubated with the indicated doses of THZ1 for 72 h, and cell viability was determined by an MTT assay. (C) Cells were pretreated with TGF-β1 for 24 h and then incubated with 0.1 μM THZ1 or 0.1 μM osimertinib for 48 h. Cell viability was determined by cell counting. (D) Cells were treated with the indicated doses of THZ1 in the presence or absence of TGF-β1 for 6 h. The indicated protein levels were analyzed by western blotting. * P < 0.05; ** P < 0.005.
3.3. Induction of Cell Cycle Arrest and Apoptosis by CDK7 Inhibitors

We have previously observed that the mechanisms of the anticancer activity of CDK7 inhibitors were associated with cell cycle arrest and the apoptosis of various cancer cells [16,32–34]. Thus, we analyzed the cell cycle and apoptosis. As shown in Figure 4, THZ1 treatment induced G2/M arrest and apoptosis in all cells (Figure 4A,B). Interestingly, the rates of G2/M arrest and apoptosis were higher in both resistant cell lines than in the parental cells (G2/M arrest = 31.6% in H1975, 50.9% in H1975/WR, 30.5% in H1975/OR; apoptosis = 22.7% in H1975, 42.1% in H1975/WR, 33.6% in H1975/OR). Consistent with these results, THZ1 treatment showed an enhancement of cleaved PARP and cleaved caspase 3 (Figure 4C).

**Figure 4.** Induction of cell cycle arrest and apoptosis by CDK7 inhibitors in parental and resistant cells. (A, B) Cells were treated with THZ1 for 24 or 48 h to analyze the cell cycle and apoptosis. The cell cycle was determined by propidium iodide (PI) staining, and apoptosis was determined by Annexin V-FITC and PI. The experiment was conducted in triplicate. (C) Cells were treated with 0.1 μM THZ1 in a time-dependent manner. Cleaved PARP and caspase-3 were detected by western blotting. ** P < 0.005; *** P < 0.0005 compared to the control group.

3.4. Recovery of the Sensitivity to EGFR-TKIs by THZ1-Tolerant Cells

Drug-tolerant (DT) cells develop within several days to several weeks of exposure to specific drugs [35,36]. We generated DT cells from H1975/WR and H1975/OR after 9 days of exposure to 100 nM THZ1. DT cells showed a 3-fold higher IC50 for THZ1 than the parental cells (Supplementary Figure S1; THZ1 IC50 = 72.4 nM in H1975/WR, 200.9 nM in 1975/WR/DT, 124.3 nM in H975/OR, 368.9 nM in H1975/OR/DT). As shown in Figure 5A, these cells showed some morphological changes similar to that seen during mesenchymal-to-epithelial transition (MET). Consistent with these results, the DT cells showed an induction of β-catenin and cytokeratin-8/18, and a reduction of vimentin, although there were no changes in expression of junction proteins, including E-cadherin and EpCAM (Figure 5B, Supplementary Figure S2). THZ1-DT cells showed a partial recovery of sensitivity to 3rd generation EGFR-TKIs (Figure 5C,D; H1975/WR/DT, IC50 = 1.2 μM and H1975/OR/DT, IC50 = 1.1 μM; H1975/WR and H1975/OR, IC50 > 10 μM). In addition, combined treatment (WZ4002 plus THZ1 in H1975/WR
cells, osimertinib plus THZ1 in H1975/OR cells) led to a restoration of sensitivity to 3rd generation EGFR-TKIs in these resistant cells (Figure 5E,F). Taken together, these data suggest that THZ1 treatment could lead to mesenchymal-to-epithelial transition in EMT-induced cells and recover their sensitivity to 3rd generation EGFR-TKIs.

Figure 5. Morphological changes and recovery of the sensitivity to EGFR-TKIs by THZ1-tolerant cells. (A) DT cells were generated by repeated exposure to 100 nM THZ1 (3 times in 9 days). Morphologic changes were determined by using a light microscope. (B) EMT-related molecules were analyzed by western blotting. (C) Cells were treated with the indicated doses of WZ4002 or osimertinib for 72 h, and cell viability was determined by the MTT assay. (D) Cells were treated with 1 µM WZ4002 or osimertinib for 48 h. Cell viability was determined by cell counting. (E,F) Cells were treated with the indicated doses of a single drug (WZ4002 or osimertinib) or in combination with 10 nM THZ1 for 72 h. Cell viability was determined by the MTT assay. * P < 0.05.
4. Discussion

EMT is associated with a poor prognosis of NSCLC patients [37,38] and acquired resistance to various anticancer drugs [39–41]. Many studies have shown that EMT affects the sensitivity to EGFR-TKIs, including primary and acquired resistance. Consistent with our studies, recent studies have revealed that EMT is a potential mechanism involved in 3rd generation EGFR-TKI resistance [42]. However, accumulating evidence has revealed that how EMT contributes to EGFR-TKIs resistance is complex and versatile. Previously, some papers demonstrated that TGF-β, IGF1R, AXL, Notch signaling, and miRNA regulating EMT-related molecules are all inducers of EMT in the development of EGFR-TKIs resistance. Although many papers have shown that the inhibition of EMT inducing molecules could overcome the acquired resistance to EGFR-TKIs, they should be studied further to optimize their efficacy in clinical practice.

CDK7 is an essential component of the transcription factor TFIIH, and it facilitates transcription initiation by phosphorylating the serine residues of RNAPII CTD (the C-terminal domain) [43,44]. Thus, CDK7 is an attractive target for anticancer treatment. Inhibition of CDK7 activity inhibits both transcription and cell cycle progression, resulting in the downregulation of anti-apoptotic proteins, such as Mcl-1 and XIAP, and cell cycle regulators, such as cyclin D1 [45]. We also showed that CDK7 inhibition led to the enhancement of G2/M arrest and apoptosis in all cell lines that were used. Although the mechanisms of anticancer effects via CDK7 inhibition have been associated with cell cycle arrest and apoptosis in various cancers [16,46,47], until recently, biomarkers for determining the sensitivity of cells to CDK7 inhibitors have been unclear.

A few limitations of this study should be taken into consideration. Firstly, while our study found that EMT was correlated with acquired resistance to EGFR-TKI, the mechanisms are not yet clear. Although KEGG pathway enrichment analysis revealed that genes involved in EMT-related pathways were enriched in 3rd generation EGFR-TKIs resistant cells (Supplementary Figure S3), further research is required to identify the specific mechanisms of action involved. Secondly, the detailed mechanisms as to why the EMT induced EGFR-TKI resistant cell lines were more sensitive to CDK7 inhibitors were not investigated. Some papers have suggested that sensitivity to CDK7 inhibitors is associated with factors such as super-enhancer-associated genes, such as SOX2, MYC, and CITED2 [48–50]. Among these, MYC and CITED2 were previously described as possible inducers of EMT [51,52], and their expression is enhanced in resistant cells (Supplementary Figure S4). Additional studies are needed to determine whether the induction of MYC or CITED2 expression in our experimental system can affect EMT and/or the sensitivity to CDK7 inhibitors.

Our results suggest that CDK7 inhibitors may be an attractive treatment option for overcoming EMT-associated EGFR-TKIs resistance. THZ1 treatment led to a reversal of the process of epithelial-to-mesenchymal transition. These phenomena resulted in the recovery of their sensitivity to 3rd generation EGFR-TKIs. Although THZ1 treatment can induce mesenchymal-to-epithelial transition (MET), we think that short-term exposure to THZ1 may help in the clearance of mesenchymal cells because mesenchymal cells are far more sensitive to THZ1 than epithelial cells. Thus, THZ1-tolerant cells can have similar characteristics to the parental cells in our experimental model. Additionally, a combined treatment of 3rd generation EGFR-TKIs and THZ1 was effective against the EMT-induced resistant cells. Our results may suggest various clinical applications to overcome EMT associated EGFR-TKIs resistance due to tumor heterogeneity.

5. Conclusions

EMT was associated with decreased sensitivity to 3rd generation EGFR-TKIs, and the EMT-related resistant cells were more sensitive to CDK7 inhibitors. This suggests the possibility of using CDK7 inhibitors as a therapeutic strategy to overcome EMT associated EGFR-TKI resistance in NSCLC.
**Supplementary Materials:** The following are available online at http://www.mdpi.com/2073-4409/9/12/2596/s1, Figure S1: IC50 values of THZ1-tolerant cells., Figure S2: Changes of EMT-related molecules in THZ1-tolerant cells., Figure S3: The analysis of RNA-seq data from parental and 3rd-generation EGFR-TKIs-resistant cells., Figure S4: Comparisons between the basal levels of parental and both resistant cell lines.

**Author Contributions:** Conceptualization, W.J., J.C.L., and J.K.R.; data curation, W.J., Y.J.C., M.-H.K., and S.J.; formal analysis, W.J. and M.-H.K.; funding acquisition, W.J. and J.K.R.; investigation, K.J.S. and D.H.K.; methodology, S.J. and C.-M.C.; project administration, J.C.L. and J.K.R.; resources, J.C.L. and J.K.R.; software, M.-H.K. and C.-M.C.; Supervision, J.C.L. and J.K.R.; validation, D.H.K. and Y.J.C.; visualization, S.J.; writing—original draft, W.J.; writing—review & editing, J.C.L. and J.K.R. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the Korean Association for Lung Cancer Research Grant 2018 (to W. Ji) and a grant from the National Research Foundation of Korea (NRF), a grant from the Korean government (2019R1A2C2006054 to J.K. Rho) and a grant (2019IF0584-1 to J.K. Rho) from the Asan Institute for Life Sciences and Corporate Relations of Asan Medical Center, Seoul, Korea.

**Acknowledgments:** The authors thank the Optical Imaging Core at the ConveRgence mEDIcine Research Center (CREDIT), Asan Medical Center, for the use of their shared equipment, services, and expertise.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Jung, K.W.; Won, Y.J.; Kong, H.J.; Lee, E.S. The Community of Population-Based Regional Cancer Registries. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2015. Cancer Res. Treat. 2018, 50, 303–316. [CrossRef] [PubMed]
2. Greenhalgh, J.; Dwan, K.; Boland, A.; Bates, V.; Vecchio, F.; Dunbar, Y.; Jain, P.; Green, J.A. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst. Rev. 2016. [CrossRef] [PubMed]
3. Westover, D.; Zugazagoitia, J.; Cho, B.C.; Lovly, C.M.; Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 2018, 29, i10–i19. [CrossRef] [PubMed]
4. Sequist, L.V.; Waltman, B.A.; Dias-Santagata, D.; Digumarthy, S.; Turke, A.B.; Fidias, P.; Bergethon, K.; Shaw, A.T.; Gettinger, S.; Cosper, A.K.; et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3, 75ra26. [CrossRef]
5. Yu, H.A.; Arcila, M.E.; Rekhtman, N.; Sima, C.S.; Zakowski, M.F.; Pao, W.; Kris, M.G.; Miller, V.A.; Ladanyi, M.; Riely, G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19, 2240–2247. [CrossRef]
6. Zhu, X.; Chen, L.; Liu, L.; Niu, X. EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and strategies. Front. Oncol. 2019, 9, 1044. [CrossRef]
7. Lamb, Y.N.; Scott, L.J. Osimertinib: A review in T790M-positive advanced non-small cell lung cancer. Target Oncol. 2017, 12, 555–562. [CrossRef]
8. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462, 1070–1074. [CrossRef]
9. Buonato, J.M.; Lazzara, M.J. ERKI/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res. 2014, 74, 309–319. [CrossRef]
10. Grünert, S.; Jechlinger, M.; Beug, H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4, 657–665. [CrossRef]
11. Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 2003, 112, 1776–1784. [CrossRef] [PubMed]
12. Shibue, T.; Weinberg, R.A. EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14, 611–629. [CrossRef] [PubMed]
13. Ye, X.; Weinberg, R.A. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 2015, 25, 675–686. [CrossRef] [PubMed]
14. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [CrossRef] [PubMed]
15. Glover-Cutter, K.; Larochelle, S.; Erickson, B.; Zhang, C.; Shokat, K.; Fisher, R.P.; Bentley, D.L. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. *Mol. Cell. Biol.* **2009**, *29*, 5455–5464. [CrossRef] [PubMed]

16. Choi, Y.J.; Kim, D.H.; Yoon, D.H.; Suh, C.; Choi, C.M.; Lee, J.C.; Hong, J.Y.; Rho, J.K. Efficacy of the novel CDK7 inhibitor Q51189 in mantle cell lymphoma. *Sci. Rep.* **2019**, *9*, 7193. [CrossRef]

17. Christensen, C.L.; Kwiatkowski, N.; Abraham, B.J.; Carretero, J.; Al-Shahrour, F.; Zhang, T.; Chipumuro, E.; Herter-Sprie, G.S.; Akbay, E.A.; Altarbef, A.; et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. *Cancer Cell* **2014**, *26*, 909–922. [CrossRef]

18. Jiang, Y.Y.; Lin, D.C.; Mayakonda, A.; Hazawa, M.; Ding, L.W.; Chien, W.W.; Xu, L.; Chen, Y.; Xiao, J.F.; Senapedis, W.; et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. *Gut* **2017**, *66*, 1358–1368. [CrossRef]

19. Li, B.; Chonghaile, T.N.; Fan, Y.; Madden, S.F.; Klinger, R.; O’Connor, A.E.; Walsh, L.; O’Hurley, G.; Mallya Udupi, G.; Joseph, J.; et al. Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer. *Cancer Res.* **2017**, *77*, 3834–3845. [CrossRef]

20. Park, J.H.; Choi, Y.J.; Kim, S.Y.; Lee, J.E.; Sung, K.J.; Park, S.; Kim, W.S.; Song, J.S.; Choi, C.M.; Sung, Y.H.; et al. Activation of the IGFR pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGFR receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer. *Oncotarget* **2016**, *7*, 22005–22015. [CrossRef]

21. Rho, J.K.; Choi, Y.J.; Kim, S.Y.; Kim, T.W.; Choi, E.K.; Yoon, S.J.; Park, B.M.; Park, E.; Bae, J.H.; Choi, C.M.; et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. *Cancer Res.* **2014**, *74*, 253–262. [CrossRef] [PubMed]

22. Rho, J.K.; Choi, Y.J.; Lee, J.K.; Ryoo, B.Y.; Na, I.I.; Yang, S.H.; Kim, C.H.; Lee, J.C. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. *Lung Cancer* **2009**, *63*, 219–226. [CrossRef] [PubMed]

23. Rho, J.K.; Choi, Y.J.; Lee, J.K.; Ryoo, B.Y.; Na, I.I.; Yang, S.H.; Lee, S.S.; Kim, C.H.; Yoo, Y.D.; Lee, J.C. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. *Mol. Cancer Res.* **2009**, *7*, 1736–1743. [CrossRef] [PubMed]

24. Zhang, Z.; Lee, J.C.; Lin, L.; Olivas, V.; Au, V.; Laframboise, T.; Abdel-Rahman, M.; Wang, X.; Levine, A.D.; Rho, J.K.; et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. *Nat. Genet.* **2012**, *44*, 852–860. [CrossRef] [PubMed]

25. Ning, J.; Ma, X.; Long, C.; Mao, Y.; Kuang, X.; Huang, Z.; Fan, Y.; Zhang, H.; Xia, Q.; Wang, R.; et al. Anti-tumor drug THZ1 suppresses TGFβ2-mediated EMT in lens epithelial cells via notch and TGFβ/smurf signaling pathway. *J. Cancer* **2019**, *10*, 3778–3788. [CrossRef] [PubMed]

26. Wang, Y.; Liu, F.; Mao, F.; Hang, Q.; Huang, X.; He, S.; Wang, Y.; Cheng, C.; Wang, H.; Xu, C.; et al. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration. *J. Biol. Chem.* **2013**, *288*, 9028–9034. [CrossRef]

27. Zhang, J.; Zhu, J.; Yang, L.; Guan, C.; Ni, R.; Wang, Y.; Ji, L.; Tian, Y. Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression. *Tumour Biol.* **2015**, *36*, 6701–6714. [CrossRef]

28. Zhou, Y.; Lu, L.; Jiang, G.; Chen, Z.; Li, J.; An, P.; Chen, L.; Du, J.; Wang, H. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer. *Cell Death Differ.* **2019**, *26*, 1442–1452. [CrossRef]

29. Akhtar, M.S.; Heidemann, M.; Tietjens, J.R.; Zhang, D.W.; Chapman, R.D.; Eick, D.; Ansari, A.Z. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. *Mol. Cell* **2009**, *34*, 387–393. [CrossRef]

30. Roy, R.; Adamczewski, J.P.; Seroz, T.; Vermeulen, W.; Tassan, J.P.; Schaeffer, L.; Nigg, E.A.; Hoeijmakers, J.H.; Egly, J.M. The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor. *Cell* **1994**, *79*, 1093–1101. [CrossRef]

31. Chung, J.H.; Rho, J.K.; Xu, X.; Lee, J.S.; Yoon, H.J.; Lee, C.T.; Choi, Y.J.; Kim, H.R.; Kim, C.H.; Lee, J.C. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. *Lung Cancer* **2011**, *73*, 176–182. [CrossRef] [PubMed]
32. Chen, H.D.; Huang, C.S.; Xu, Q.C.; Li, F.; Huang, X.T.; Wang, J.Q.; Li, S.J.; Zhao, W.; Yin, X.Y. Therapeutic targeting of CDK7 suppresses tumor progression in intrahepatic cholangiocarcinoma. *Int. J. Biol. Sci.* 2020, 16, 1207–1217. [CrossRef]

33. Patel, H.; Periyasamy, M.; Sava, G.P.; Bondke, A.; Slafer, B.W.; Kroll, S.H.B.; Barbazanges, M.; Starkey, R.; Ottaviani, S.; Harrod, A.; et al. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. *Mol. Cancer Ther.* 2018, 17, 1156–1166. [CrossRef]

34. Zhang, Y.; Zhou, L.; Bandyopadhyay, D.; Sharma, K.; Allen, A.J.; Kmieciak, M.; Grant, S. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. *Clin. Cancer Res.* 2019, 25, 6195–6205. [CrossRef]

35. Okura, N.; Nishioka, N.; Yamada, T.; Taniguchi, H.; Tanimura, K.; Katayama, Y.; Yoshimura, A.; Watanabe, S.; Kikuchi, T.; Shiotzu, S.; et al. ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer. *Clin. Cancer Res.* 2020, 26, 2244–2256. [CrossRef]

36. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizi, N.; Zhou, L.; Fischbach, M.A.; et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. *Cell* 2010, 141, 69–80. [CrossRef] [PubMed]

37. Bremnes, R.M.; Veve, R.; Gabrielson, E.; Hirsch, F.R.; Baron, A.; Bemis, L.; Gemmill, R.M.; Drabkin, H.A.; Franklin, W.A. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. *J. Clin. Oncol.* 2002, 20, 2417–2428. [CrossRef] [PubMed]

38. Deeb, G.; Wang, J.; Ramnath, N.; Slocum, H.K.; Wiseman, S.; Beck, A.; Tan, D. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. *Mod. Pathol.* 2004, 17, 430–439. [CrossRef] [PubMed]

39. Fischer, K.R.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.; Choi, H.; Rayes, T.E.; Ryu, S.; Troeger, J.; et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. *Nature* 2015, 527, 472–476. [CrossRef]

40. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. *Nat. Rev. Cancer* 2013, 13, 714–726. [CrossRef]

41. Zheng, X.; Carstens, J.L.; Kim, J.; Scheible, M.; Kaye, J.; Sugimoto, H.; Wu, C.C.; LeBleu, V.S.; Kalluri, R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* 2015, 527, 525–530. [CrossRef] [PubMed]

42. Weng, C.H.; Chen, L.Y.; Lin, Y.C.; Shih, J.Y.; Lin, Y.C.; Tseng, R.Y.; Chiu, A.C.; Yeh, Y.H.; Liu, C.; Lin, Y.T.; et al. Epithelial-mesenchymal transition beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. *Oncogenes* 2019, 38, 455–468. [CrossRef] [PubMed]

43. Fisher, R.P. Secrets of a double agent: CDK7 in cell-cycle control and transcription. *J. Cell Sci.* 2005, 118, 5171–5180. [CrossRef] [PubMed]

44. Fisher, R.P. The CDK Network: Linking cycles of cell division and gene expression. *Genes Cancer* 2012, 3, 731–738. [CrossRef] [PubMed]

45. Wesierska-Gadek, J.; Borza, A.; Komina, O.; Maurer, M. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: Bi-functionalization increases its therapeutic potential. *Acta Biochim. Pol.* 2009, 56, 495–501. [CrossRef] [PubMed]

46. Huang, J.R.; Qin, W.M.; Wang, K.; Fu, D.R.; Zhang, W.J.; Jiang, Q.W.; Yang, Y.; Yuan, M.L.; Xing, Z.H.; Wei, M.N.; et al. Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo. *Am. J. Transl. Res.* 2018, 10, 3664–3676. [CrossRef]

47. Wang, B.Y.; Liu, Q.Y.; Cao, J.; Chen, J.W.; Liu, Z.S. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer. *Drug Des. Devel Ther* 2016, 10, 1181–1189. [CrossRef]

48. Chipumuro, E.; Marco, E.; Christensen, C.L.; Kwiatkowski, N.; Zhang, T.; Hatheway, C.M.; Abraham, B.J.; Sharma, B.; Yeung, C.; Aalatbe, A.; et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. *Cell* 2014, 159, 1126–1139. [CrossRef]
49. Hur, J.Y.; Kim, H.R.; Lee, J.Y.; Park, S.; Hwang, J.A.; Kim, W.S.; Yoon, S.; Choi, C.M.; Rho, J.K.; Lee, J.C. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification. *Cell. Oncol.* 2019, 42, 449–458. [CrossRef]

50. McDermott, M.S.J.; Sharko, A.C.; Munie, J.; Kassler, S.; Melendez, T.; Lim, C.U.; Broude, E.V. CDK7 inhibition is effective in all the subtypes of breast cancer: Determinants of response and synergy with EGFR inhibition. *Cells* 2020, 9, 638. [CrossRef]

51. Shin, S.H.; Lee, G.Y.; Lee, M.; Kang, J.; Shin, H.W.; Chun, Y.S.; Park, J.W. Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway. *Nat. Commun.* 2018, 9, 4113. [CrossRef] [PubMed]

52. Yin, S.; Cheryan, V.T.; Xu, L.; Rishi, A.K.; Reddy, K.B. Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells. *PLoS ONE* 2017, 12, e0183578. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).